# Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)

> **NCT02564536** · PHASE1 · WITHDRAWN · sponsor: **Washington University School of Medicine**

## Conditions studied

- Chronic Myelomonocytic Leukemia
- Juvenile Myelomonocytic Leukemia
- Atypical Chronic Myeloid Leukemia
- Myeloproliferative Neoplasm
- Myelodysplastic Syndromes
- Myelofibrosis

## Interventions

- **DRUG:** Pacritinib
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT02564536
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-06
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding following full FDA clinical hold
- **Last updated:** 2017-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02564536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02564536, "Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02564536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*